Clinical Trials on Pandemic Influenza in Belgium

Total 114 results

Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
Lieselot Houspie

Unknown

Nasal Specimen Collection Study in Patients With ILI and/or ARI in an Outpatient Setting

Influenza-like Illness | Influenzal Acute Respiratory Infection

Belgium
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
University Hospital, Ghent
GlaxoSmithKline; Novartis Vaccines; University of Surrey; Innovative Medicines... and other collaborators

Completed

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

Safety Markers of Adjuvanted Influenza Vaccine

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Osivax
Center for vaccinology (CEVAC), University of Ghent

Completed

Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

Influenza

Belgium
Osivax
Centre for vaccinology (CEVAC), University of Ghent

Completed

Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Influenza

Belgium
Osivax
Center for vaccinology (CEVAC), University of Ghent, Belgium

Completed

A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Visterra, Inc.

Completed

Influenza Challenge Study of VIS410 in Healthy Volunteers

Influenza

Belgium
Crucell Holland BV

Completed

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

Influenza

Belgium
Novartis
Novartis Vaccines

Completed

A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age

Influenza

Belgium
Cyril Barbezange
Sciensano; Belgian Federal Public Service, Food Chain Safety and Environment; Agentschap Zorg en Gezondheid

Enrolling by invitation

Zoonotic Influenza Surveillance in Belgium (ZOOIS)

Influenza, Human

Belgium
Osivax
Aepodia

Completed

Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

Influenza

Belgium
GlaxoSmithKline

Completed

Revaccination With Influenza Vaccine GSK1247446A

Influenza | Influenza, Human

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' FluLaval® TF

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults

Influenza

Belgium
Universiteit Antwerpen
Yakult Honsha Co., LTD

Completed

Study of the Effect of Probiotics on Respiratory Morbidity After Influenza Vaccination of Elderly in Nursing Homes

Respiratory Tract Infections

Belgium
LiteVax BV
University Hospital, Ghent

Completed

Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin (TETRALITE-I)

Influenza

Belgium
Vaccitech (UK) Limited

Completed

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Influenza

Belgium
Atriva Therapeutics GmbH
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ATR-002

Influenza

Belgium
LiteVax BV
University Hospital, Ghent; HarmonyCR, Melle, Belgium

Recruiting

Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine (TETRALITE-Ib)

Vaccination Reaction

Belgium
Universitaire Ziekenhuizen KU Leuven

Recruiting

Influenza Associated Aspergillosis In-depth Investigation (PIAS)

Invasive Pulmonary Aspergillosis | Influenza With Pneumonia

Belgium
Solvay Pharmaceuticals

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.

Healthy Volunteers

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

Influenza

Belgium
Erasme University Hospital
Roche Diagnostics; LHUB-ULB

Terminated

Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room

RSV Infection | Influenza Viral Infections

Belgium

3

Subscribe